A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

Inclusion Criteria10

• Voluntary participation and ability to sign informed consent (post-TACE);
• Age between 18 and 75 years;
• Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B;
• Patients undergo contrast-enhanced spectral CT 4-8 weeks after treatment and are assessed as complete response on conventional CT images;
• Patients are scheduled to undergo surgical resection within one month, or DSA hepatic arteriography or contrast-enhanced MRI within one week. If none of these were planned, the patients were scheduled for imaging follow-up (CT or MRI) every 3 months (±15 days) for at least one year.
• Voluntary participation and ability to sign informed consent (post-TACE, cTACE or DEB-TACE);
• Age between 18 and 75 years;
• Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B;
• Patients plan to undergo liver tumor resection following TACE downstaging therapy;
• Contrast-enhanced spectral CT was performed within 7 days before liver resection, after completion of TACE down-staging treatment.